Specialty pharma company Pharmalink AB has elected Maria Carell as Chair of the Board of Directors. Carell replaces Hilde Furberg, who will take over as Vice Chair.
Barcelona-based epigenetics specialist Oryzon Genomics has made new additions to its Scientific Advisory Board in order to be prepared for the completion of its Phase I trial for dementia drug ORY-2001. Renowned Alzheimers disease expert Howard Fillit will take over a seat on the board.
Going forward, Henrik Birk will be in charge of Bavarian Nordics operational and HR strategies. He will take over the newly created position of Chief Operating Officer at the Danish-German biotech.
YposKesi, developer of gene and cell therapy products for rare diseases, has appointed Alain Lamproye as its CEO. Lamproye, an expert in industrial bioproduction, most recently served as Chairman of the BioPharma Business Unit of Novaseps Belgian gene therapy subsidiary.
BenevolentAI has hired a Chief Medical Officer making it the first artificial intelligence company to do so. Patrick Keohane will take up position of CMO at BenevolentBio. The subsidiary of BenevolentAI aims to apply its AI to develop meds, and plans to find other uses for AI in bioscience as well.
German lab equipment provider Sartorius has appointed Rainer Lehmann to the Executive Board. Lehmann will be overseeing the Finance, Human Resources Management and Information Technology functions.
Henrik Luessen is taking over as Chief Business Officer at Promethera Biosciences SA, Belgian developer of cell-based meds. He will be responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
Lund-based probiotics expert Probi AB has appointed Jörn Andreas as new CFO. He will replace Niklas Brandt, who in turn will take over responsibility for IT infrastructure and IR as CIO.
Pfizers Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).
Starting in May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologens DNA cancer therapy lefitolimod for market launch.